Search

Displaying results 7901 - 7910 of 10000 in total
  1. Drug

    Vatalanib

    go.drugbank.com/drugs/DB04879
    Investigational

    Vatalanib is under investigation for the treatment of solid tumors. … Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors.

  2. Drug

    Picoplatin

    go.drugbank.com/drugs/DB04874
    Investigational

    Picoplatin is a cytotoxic platinum compound in clinical development for the treatment of patients with solid tumors.

  3. Drug

    Lanoteplase

    go.drugbank.com/drugs/DB06245
    Experimental

  4. Drug

    CMC 001

    go.drugbank.com/drugs/DB05353
    Investigational

    CMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.

  5. Drug

    BBV152

    go.drugbank.com/drugs/DB15847
    Investigational

    or a novel TLR7/8 agonist adsorbed gel. … BBV152 is a vaccine candidate created by the Indian Council of Medical Research (ICMR).

  6. Drug

    XEN-D0101

    go.drugbank.com/drugs/DB06020
    Experimental

    XEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.

  7. Drug

    N-Formylmethionine

    go.drugbank.com/drugs/DB04464
    Experimental

    This process occurs in Escherichia coli and other bacteria as well as in the mitochondria of eucaryotic cells. … N-Formylmethionine is effective in the initiation of protein synthesis. The initiating methionine residue enters the ribosome as N-formylmethionyl tRNA.

  8. Drug

    Terguride

    go.drugbank.com/drugs/DB13399
    Experimental

    Categories: Heterocyclic Compounds with 4 or More Rings
  9. Drug

    Butyrylcholinesterase

    go.drugbank.com/drugs/DB06352
    Investigational

  10. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.